Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cytori Therapeutics
Cytori Begins Breast Reconstruction Study in Europe
May 13th, 2008
Cytori (NASDAQ:CYTX) received approval to begin its European stem and regenerative cell-enhanced breast reconstruction study in breast cancer patients who have undergone partial mastectomy. This is a post-market study designated as RESTORE II. Currently, there is no generally accepted reconstructive technique for partial mastectomy patients despite the fact that breast conserving therapy is standard practice in the treatment of women with breast cancer worldwide. In this study, tissue loss resulting from partial mastectomy will be reconstructed with the patients' own fat tissue (adipose), which will be enhanced with their adipose-derived stem and regenerative cells....
Source: Cancer Weekly (2008-05-13)
|
